Seamlessly incorporate publishing activities within Veeva Vault RIM for end-to-end submission development
PLEASANTON, CA — Sept 5, 2018 — Veeva Systems (NYSE:VEEV) today announced the availability of Veeva Vault Submissions Publishing, a new cloud application in the Veeva Vault RIM Suite to unify publishing and submission document authoring. Vault Submissions Publishing automatically publishes and validates documents as they are authored and approved so regulatory teams complete work earlier. Now life sciences organizations can speed submission delivery with seamless traceability, from planning through transmission to the health authority gateway, within a single unified RIM platform.
Submission planning, content management, publishing, validation, and transmission are typically completed in separate systems, creating inefficiency when documents are transferred internally. System silos also delay publishing until the submission documents are finalized, when timelines are most pressing.
“Veeva Vault Submissions Publishing allows us to bring together publishing activities with document planning, authoring, and approval to streamline the entire submission development process,” said Shelly Plapp, director of regulatory operations at Melinta Therapeutics. “Now we can conduct publishing activities earlier and complete submissions much faster.”
Veeva Vault Submissions Publishing enables a continuous publishing process for sponsors to finish publishing steps sooner so validation issues are identified and fixed faster. It also allows teams to eliminate moving documents between multiple systems and reduce the number of document transfers to one – when the dossier is transmitted directly to a health authority.
“Veeva Vault Submissions Publishing unifies regulatory activities within the Vault RIM Suite and across the submission development lifecycle,” said John Lawrie, vice president of Veeva Vault RIM. “When there’s a product-related change, Vault RIM customers can trace impacted registrations to the corresponding submissions, authored content, and published output all in a single system.”
The Vault RIM Suite provides fully integrated RIM capabilities to manage product registrations, health authority correspondence and commitments, submission documents, and published dossiers on a single cloud platform. Vault RIM is part of Veeva Development Cloud, a unified suite of applications for clinical, regulatory, and quality to help organizations drive end-to-end business processes across R&D and manufacturing.
Also, be sure to join 1,300 life sciences professionals and experts at the upcoming Veeva R&D Summit in Philadelphia, September 16-18. Learn more, register, and view the full agenda at veeva.com/R&DSummit.
For more on Veeva Vault Submissions Publishing, visit: veeva.com/VaultPublishing
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 650 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended April 30, 2018. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.